ZYDELIG® (Idelalisib)

The FDA on July 23, 2014 approved ZYDELIG® for the treatment of patients with relapsed Chronic Lymphocytic Leukemia (CLL), in combination with Rituximab (RITUXAN®), for whom RITUXAN® alone would be considered appropriate therapy due to other co-morbidities. ZYDELIG® tablets are a product of Gilead Sciences, Inc.